Cancer immunotherapies with antibodies that target immune checkpoint molecules have demonstrated therapeutic efficacy and durable response for several tumor types.30 The prognostic values of 71 key immune checkpoint molecules were determined in GBM by Kaplan-Meier analysis, showing that the expression level of 3 immune stimulators—ICOS, TNFSF14, and ULBP1, which were negatively correlated with the clinical outcome of patients with GBM. Here, TNFSF14 is linked to cancer.